We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

This study is currently recruiting participants.
Verified March 2017 by Miguel Martín Jiménez, Hospital General Universitario Gregorio Marañon
Sponsor:
ClinicalTrials.gov Identifier:
NCT01560663
First Posted: March 22, 2012
Last Update Posted: March 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
UNC Lineberger Comprehensive Cancer Center
Hospital Universitario Ramon y Cajal
Hospital San Carlos, Madrid
Centro Nacional de Investigaciones Oncologicas CARLOS III
Information provided by (Responsible Party):
Miguel Martín Jiménez, Hospital General Universitario Gregorio Marañon
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)